These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 29410326)
1. Is gentamicin safe and effective for severe community-acquired pneumonia? An 8-year retrospective cohort study. Brereton CJ; Lennon D; Browning S; Dunn E; Ferguson JK; Davis JS Int J Antimicrob Agents; 2018 Jun; 51(6):862-866. PubMed ID: 29410326 [TBL] [Abstract][Full Text] [Related]
2. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787 [TBL] [Abstract][Full Text] [Related]
3. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis. Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381 [TBL] [Abstract][Full Text] [Related]
4. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913 [TBL] [Abstract][Full Text] [Related]
5. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus. So W; Crandon JL; Nicolau DP Intern Emerg Med; 2016 Jun; 11(4):545-51. PubMed ID: 26531307 [TBL] [Abstract][Full Text] [Related]
6. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan. Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home. Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506 [TBL] [Abstract][Full Text] [Related]
8. Intermediate risk of multidrug-resistant organisms in patients who admitted intensive care unit with healthcare-associated pneumonia. Lee H; Park JY; Lee T; Lee YJ; Lim HJ; Park JS; Yoon HI; Lee JH; Lee CT; Cho YJ Korean J Intern Med; 2016 May; 31(3):525-34. PubMed ID: 26968189 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807 [TBL] [Abstract][Full Text] [Related]
10. Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. Lentino JR; Krasnicka B Int J Antimicrob Agents; 2002 Jan; 19(1):61-6. PubMed ID: 11814769 [TBL] [Abstract][Full Text] [Related]
11. Impact of an antimicrobial stewardship program on outcomes in patients with community-acquired pneumonia admitted to a tertiary community hospital. Gordon K; Stevens R; Westley B; Bulkow L Am J Health Syst Pharm; 2018 Jun; 75(11 Supplement 2):S42-S50. PubMed ID: 29802178 [TBL] [Abstract][Full Text] [Related]
12. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123 [TBL] [Abstract][Full Text] [Related]
14. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy. DiMondi VP; Drew RH; Chen LF Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323 [TBL] [Abstract][Full Text] [Related]
15. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Falguera M; Carratalà J; Ruiz-Gonzalez A; Garcia-Vidal C; Gazquez I; Dorca J; Gudiol F; Porcel JM Respirology; 2009 Jan; 14(1):105-11. PubMed ID: 18699803 [TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms. Goldstein RC; Husk G; Jodlowski T; Mildvan D; Perlman DC; Ruhe JJ Am J Infect Control; 2014 May; 42(5):539-41. PubMed ID: 24773792 [TBL] [Abstract][Full Text] [Related]
17. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of azithromycin infusion in patients with mild or moderate community-acquired pneumonia]. Noguchi S; Yatera K; Kawanami T; Yamasaki K; Uchimura K; Hata R; Tachiwada T; Oda K; Hara K; Suzuki Y; Akata K; Ogoshi T; Tokuyama S; Inoue N; Nishida C; Orihashi T; Yoshida Y; Kawanami Y; Taura Y; Ishimoto H; Obata H; Tsuda T; Yoshii C; Mukae H Jpn J Antibiot; 2014 Jun; 67(3):193-203. PubMed ID: 25163252 [TBL] [Abstract][Full Text] [Related]
19. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768 [TBL] [Abstract][Full Text] [Related]
20. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. Zasowski E; Butterfield JM; McNutt LA; Cohen J; Cosler L; Pai MP; Gottwald J; Chen WZ; Lodise TP Antimicrob Agents Chemother; 2014 Jul; 58(7):3804-13. PubMed ID: 24752270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]